Solomon Getawa

Mr. Solomon Getawa

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Global Pediatric Health
Verified
Journal Article
Open access
SGSolomon Gedfie
Solomon Gedfie
SGSolomon Getawa
Solomon Getawa
MMMulugeta Melku
Mulugeta Melku
Background. Iron deficiency anemia is a common health problem that affects children under the age of five. Children’s cognitive performance is impaired by iron deficiency, which impacts their psychomotor development. Therefore, the aim of this study was to determine the global prevalence and associated factors of iron deficiency and iron deficiency anemia among under-5 children. Methods. Relevant publications published till March 30, 2021 were identified in databases such as Medline/PubMed, Science Direct, Popline, EMBASE, African Journals Online, Scopus, and Google Scholar. The STATA version 11 software was utilized for the analysis. To determine the level of heterogeneity, I2 test statistics were used. To detect publication bias, funnel plots analysis and the Egger weighted regression test were used. Results. The global pooled prevalence of iron deficiency anemia and iron deficiency was 16.42% (95% CI: 10.82, 22.01) and 17.95% (95% CI: 13.49, 22.41), respectively. Age less than 2 years (OR = 1.26; 95% CI: 1.14, 1.38) and living in a large family size (OR = 1.38; 95% CI: 1.18, 1.58) were associated with iron deficiency anemia. Children born from anemic mother, low birth weight, and do not drink iron fortified milk (OR = 1.20; 95% CI: 1.05, 1.36), (OR = 1.15; 95% CI: 1.01, 1.36) and (OR = 1.28; 95% CI: 1.10, 1.46), respectively were associated factors of iron deficiency in under-5 children. Conclusion. The prevalence of iron deficiency anemia and iron deficiency was significant across the globe, particularly in Asia and Africa. Therefore, regular screening and treatment of iron deficiency and iron deficiency anemia are required especially in high-risk children to reduce their complication. PROSPERO registration number: CRD42021267060

3 June 2023 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
TATiruneh Adane
Tiruneh Adane
MMMulugeta Melku
Mulugeta Melku
YWYilkal Belete Worku
Yilkal Belete Worku
AFAlebachew Fasil
Alebachew Fasil
MAMelak Aynalem
Melak Aynalem
SGSolomon Getawa
Solomon Getawa
Background. Glycated hemoglobin (HbA1c) is a commonly used clinical marker to monitor the control of type 2 diabetes mellitus patients (T2DM). However, it is unable to identify the ongoing inflammatory changes in the body. These factors could be easily identified and monitored by the neutrophil-to-lymphocyte ratio (NLR). Therefore, this study is aimed at investigating the relationship between NLR and glycemic control in T2DM. Method. A comprehensive search of eligible studies was performed in various databases published until July 2021. A random effect model was used to estimate the standardized mean difference (SMD). A metaregression, subgroup, and sensitivity analysis were conducted to search for potential sources of heterogeneity. Result. A total of 13 studies were included in this study. Accordingly, the SMD of the NLR values between the poor and good glycemic control groups was 0.79 (95% CI, 0.46-1.12). Our study also showed that high NLR was significantly associated with poor glycemic control in T2DM patients ( , 95% CI: 1.30-1.93). Conclusion. The results of this study suggest an association between high NLR values and an elevated HbA1C in T2DM patients. Therefore, NLR should be considered a marker of glycemic control in addition to HbA1c in T2DM patients.

18 August 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
TATiruneh Adane
Tiruneh Adane
SGSolomon Getawa
Solomon Getawa
Background: Coagulation mechanisms are reported to be affected in dengue illness and evidenced by prolonged activated partial thromboplastin time (APTT) and prothrombin time (PT). The main aim of this systematic review and meta-analysis is to determine the magnitude of coagulation abnormalities among patients with dengue fever infection. Method: This systematic review and meta-analysis were conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. The Joana Brigg’s Institute (JBI) critical appraisal checklist was used for quality appraisal. STATA version 11 software was used for meta-analysis. The magnitude of coagulation abnormalities among dengue fever patients was determined by using a random-effects model. Subgroup and sensitivity analysis were performed to investigate the possible source of heterogeneity. Egger weighted regression tests were used to check the presence of publication bias among the included articles. Result: Forty-two studies with a total of 12,221 dengue fever patients were eligible for meta-analysis in this study. Of which 22, 15, and 26 studies were used to determine the magnitude of prolonged APTT, PT, and thrombocytopenia, respectively. The magnitude of prolonged APTT and PT among patients with dengue fever infection were 42.91% (95% CI: 30.95, 54.87) I2 = 99.1% and 16.48% (95% CI: 10.95, 22.01) I2 = 97.0%, respectively. Besides, the magnitude of thrombocytopenia among dengue fever patients was 70.29% (95% CI: 62.69, 77.89) I2 = 99.3%. The magnitude of prolonged APTT in children and adults was 51.21% (95% CI: 24.54, 77.89) and 44.89% (95% CI: 28.32, 61.45), respectively. Similarly, the overall magnitude of prolonged PT in children and adults were 13.40% (95% CI: 6.09, 20.71) and 18.73% (95% CI: 7.49, 29.96), respectively. Conclusion: The result of this study showed that there is a high magnitude of prolonged APTT and PT in dengue fever patients. Therefore, screening and early correction of coagulation abnormalities may be helpful to reduce further complications in those patients.

19 December 2022 in Practical Laboratory Medicine
Verified
Journal Article
Open access
SGSolomon Getawa
Solomon Getawa
MAMelak Aynalem
Melak Aynalem
MMMulugeta Melku
Mulugeta Melku
TATiruneh Adane
Tiruneh Adane
Clinical laboratory errors have a great impact on patient safety and treatment. Although specimen rejections result in longer turnaround times and increased health-care costs, different studies present inconsistent findings. Therefore, the study aimed to determine the pooled prevalence of blood specimen rejection in clinical laboratory. Electronic databases including MEDLINE, PubMed, EMBASE, HINARI, Cochrane Library, Google Scholar, and Science Direct were comprehensively searched. Articles were screened and the data extracted independently by authors. Publication bias was checked by funnel-plots and Egger's statistical test. Pooled prevalence was estimated using a random-effects model. The I2 statistical test were performed to assess heterogeneity. The possible sources of heterogeneity were analyzed through subgroup and sensitivity analysis. Total of 26 articles with 16,118,499 blood sample requests were included in the meta-analysis. The pooled prevalence of blood specimen rejection in the clinical laboratory was 1.99% (95% CI: 1.73, 2.25). Subgroup analysis showed that, the highest prevalence of specimen rejection was observed in Asia [2.82% (95%CI: 2.21, 3.43)] and lowest in America [0.55% (95%CI: 0.27, 0.82)]. The leading cause of blood specimen rejection in clinical laboratories were clotted specimen (32.23% (95%CI: 21.02, 43.43)), hemolysis (22.87% (95%CI: 16.72, 29.02)), insufficient volume (22.81% (95%CI: 16.75, 28.87)), and labelling errors (7.31% (95%CI: 6.12, 8.58)). The pooled prevalence of blood specimen rejection rate is relatively high especially in developing regions. Therefore, proper training for specimen collectors, compliance with good laboratory practices specific to specimen collection, transportation, and preparation is required to reduce the rejection rate.

8 August 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMelak Aynalem
Melak Aynalem
NANurayni Adem
Nurayni Adem
FWFirdews Wendesson
Firdews Wendesson
BMBewket Misganaw
Bewket Misganaw
SMSimegnew Mintesnot
Simegnew Mintesnot
ESElias Shiferaw
Elias Shiferaw
Background: Breast cancer is the most frequent and fatal cancer type globally. The fatality rate of breast cancer is mostly due to disease complications like hematological alterations. Therefore, this study aimed to assess the hematological abnormalities before, during, and after the initiation of cancer treatment in breast cancer patients at the University of Gondar comprehensive specialized hospital. Methodology: Hematological profiles were collected from 267 breast cancer patients who attended the cancer treatment center from September 2017 to August 2021. A data extraction sheet was used to extract data from the patient’s medical chart, including sociodemography, clinical, and hematological profiles. EPI info version 3.5.1 and SPSS Version 25 softwares were used for data entrance and analysis, respectively. Descriptive statistics were summarized using frequency and percentage. The Friedman test followed by a Wilcoxon signed rank test was used to compare the mean difference between the hematological profiles at zero and after the 4th and 8th cycles of treatment. Result: Of the total participants, 91% were females, and the median age of the study participants was 45 (IQR = 36, 55) years. Red blood cell, white blood cell, and lymphocyte counts, as well as hematocrit and hemoglobin values, were significantly reduced after the initiation of cancer treatment, while the platelet count and red cell distribution width were significantly increased. The prevalence of anemia was 21.7% (95% CI: 16.6, 26.8), 22.7% (95% CI: 17.6, 27.8), and 26.4% (95% CI: 21.3, 31.5) before, during, and after the initiation of cancer treatment, respectively. The prevalence of leukopenia before, during, and after treatment was 9.7%, 18.8%, and 15.1%, respectively. Finally the prevalence of thrombocytopenia was 6.3%, 3.4%, and 8% at before, during, and after treatment, respectively. Conclusion: This study concluded that many hematological parameters were significantly affected by the breast cancer treatment. Therefore, proper patient follow-up and provide appropriate interventions related to their hematological abnormalities is crucial. It is also important to conduct further prospective studies to confirm the findings of this study.

4 November 2022 in Medicine
Verified
Journal Article
Open access
TATiruneh Adane
Tiruneh Adane
MMMulugeta Melku
Mulugeta Melku
GAGetnet Msc Ayalew
Getnet Msc Ayalew
GBGezahegn Msc Bewket
Gezahegn Msc Bewket
MAMelak Aynalem
Melak Aynalem
SGSolomon Getawa
Solomon Getawa
Background: High monocyte to lymphocyte ratio (MLR) values may be associated with the risk of active tuberculosis (TB) infection in adults, infants, and postpartum women with HIV infection. It may also serve as an indicator of the effectiveness of anti-TB treatment. Thus, the main aim of this study is to ascertain the accuracy of MLR for the diagnosis of TB and its role in monitoring the effectiveness of anti-TB therapy. Methods: This systematic review and meta-analysis followed the preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. All statistical analyses were performed using STATA 11 and Meta-DiSc software. The Quality assessment of Diagnostic Accuracy Studies tool was used to evaluate the methodological quality of the included studies. The area under the hierarchical summary receiver-operating characteristic hierarchical summary ROC curve [(HSROC) curve (AUC)] was also calculated as an indicator of diagnostic accuracy. Results: A total of 15 articles were included in this study. Accordingly, the result showed that elevated MLR is associated with increased risks of TB disease [odd ratio = 3.11 (95% CI: 1.40–6.93)]. The pooled sensitivity and specificity of MLR for identifying TB were 79.5% (95% CI: 68.5–87.3) and 80.2% (95% CI: 67.3–88.9), respectively. The AUC of HSROC was 0.88 (95% CI: 0.857–0.903), indicating the excellent diagnostic performance of MLR for TB. This study also showed that there is a significant reduction in the MLR value after anti-TB treatment in TB patients (standardized mean difference = 0.68; 95% CI: 0.007, 1.43). Conclusions: Generally, MLR can be considered as a crucial biomarker to identify TB and monitor the effectiveness of anti-TB therapy.